| P50 | author | Janet Daling | Q20807295 |
| | Susan R Heckbert | Q88077554 |
| | Diana Miglioretti | Q88168881 |
| | Diana Buist | Q91924352 |
| | Denise M Boudreau | Q92838606 |
| P2093 | author name string | Onchee Yu | |
| P2860 | cites work | The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | Q29547887 |
| | Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial | Q29617817 |
| | The use of automated data to identify complications and comorbidities of diabetes: a validation study | Q31271125 |
| | Carcinogenicity of lipid-lowering drugs | Q34368492 |
| | HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis | Q34605246 |
| | The statins as anticancer agents | Q35049816 |
| | The influence of statin use on breast density | Q36121798 |
| | Statins and cancer development. | Q36231567 |
| | Statin use and breast cancer: prospective results from the Women's Health Initiative. | Q36480676 |
| | Statin use, hyperlipidaemia, and the risk of breast cancer | Q36644431 |
| | Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells | Q38358594 |
| | Statins can inhibit proliferation of human breast cancer cells in vitro | Q40668259 |
| | Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study | Q40790232 |
| | Anti-carcinogenic activity of simvastatin during the promotion phase of radiation-induced mammary tumorigenesis of rats | Q42445330 |
| | Statin use and the risk of breast and prostate cancer | Q43966555 |
| | Serum lipids, lipid-lowering drugs, and the risk of breast cancer | Q46772398 |
| | Revisions in the risk-based Breast Cancer Screening Program at Group Health Cooperative. | Q52475051 |
| | The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. | Q53368104 |
| | Lipid-Lowering Drug Use and Breast Cancer in Older Women: A Prospective Study | Q58217064 |
| | Statin use and the risk of breast cancer | Q73341602 |
| | 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study | Q74116896 |
| | Evaluating organized breast cancer screening implementation: the prevention of late-stage disease? | Q76370726 |
| | Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis | Q77513498 |
| | Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications | Q80102857 |
| | A population-based osteoporosis screening program: who does not participate, and what are the consequences? | Q80226406 |
| | Following positive epidemiologic studies, statins to enter clinical trials for cancer prevention | Q81074403 |
| | A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes | Q83222519 |
| | Lipophilic statins merit additional study for breast cancer chemoprevention | Q83222522 |
| | Statins and breast cancer prevention: time for randomized controlled trials | Q83222526 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 416-421 | |
| P577 | publication date | 2007-03-01 | |
| P1433 | published in | Cancer Epidemiology, Biomarkers & Prevention | Q326334 |
| P1476 | title | Statin use and breast cancer risk in a large population-based setting | |
| P478 | volume | 16 | |